These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36576574)

  • 1. PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report.
    Lehto J; Sucksdorff M; Nylund M; Raitanen R; Matilainen M; Airas L
    J Neurol; 2023 Apr; 270(4):2329-2332. PubMed ID: 36576574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.
    Sucksdorff M; Matilainen M; Tuisku J; Polvinen E; Vuorimaa A; Rokka J; Nylund M; Rissanen E; Airas L
    Brain; 2020 Dec; 143(11):3318-3330. PubMed ID: 33006604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis.
    Lehto J; Nylund M; Matilainen M; Sucksdorff M; Vuorimaa A; Rajander J; Wahlroos S; Hariri P; Airas L
    Eur J Neurol; 2023 Aug; 30(8):2365-2375. PubMed ID: 37154404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome.
    Giannetti P; Politis M; Su P; Turkheimer FE; Malik O; Keihaninejad S; Wu K; Waldman A; Reynolds R; Nicholas R; Piccini P
    Brain; 2015 Jan; 138(Pt 1):110-9. PubMed ID: 25416179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.
    Datta G; Colasanti A; Rabiner EA; Gunn RN; Malik O; Ciccarelli O; Nicholas R; Van Vlierberghe E; Van Hecke W; Searle G; Santos-Ribeiro A; Matthews PM
    Brain; 2017 Nov; 140(11):2927-2938. PubMed ID: 29053775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹C-PK11195.
    Rissanen E; Tuisku J; Rokka J; Paavilainen T; Parkkola R; Rinne JO; Airas L
    J Nucl Med; 2014 Jun; 55(6):939-44. PubMed ID: 24711650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis.
    Bodini B; Poirion E; Tonietto M; Benoit C; Palladino R; Maillart E; Portera E; Battaglini M; Bera G; Kuhnast B; Louapre C; Bottlaender M; Stankoff B
    J Nucl Med; 2020 Jul; 61(7):1043-1049. PubMed ID: 32005777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
    Galego O; Gouveia A; Batista S; Moura C; Machado E
    Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18)F-PBR111 PET.
    Colasanti A; Guo Q; Muhlert N; Giannetti P; Onega M; Newbould RD; Ciccarelli O; Rison S; Thomas C; Nicholas R; Muraro PA; Malik O; Owen DR; Piccini P; Gunn RN; Rabiner EA; Matthews PM
    J Nucl Med; 2014 Jul; 55(7):1112-8. PubMed ID: 24904112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab treatment reduces microglial activation in the white matter of the MS brain.
    Sucksdorff M; Tuisku J; Matilainen M; Vuorimaa A; Smith S; Keitilä J; Rokka J; Parkkola R; Nylund M; Rinne J; Rissanen E; Airas L
    Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e574. PubMed ID: 31355310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two different methods of image analysis for the assessment of microglial activation in patients with multiple sclerosis using (R)-[N-methyl-carbon-11]PK11195.
    Kang Y; Schlyer D; Kaunzner UW; Kuceyeski A; Kothari PJ; Gauthier SA
    PLoS One; 2018; 13(8):e0201289. PubMed ID: 30091993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelin water imaging reflects clinical variability in multiple sclerosis.
    Kolind S; Matthews L; Johansen-Berg H; Leite MI; Williams SC; Deoni S; Palace J
    Neuroimage; 2012 Mar; 60(1):263-70. PubMed ID: 22155325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study.
    Pitombeira MS; Koole M; Campanholo KR; Souza AM; Duran FLS; Solla DJF; Mendes MF; Pereira SLA; Rimkus CM; Busatto GF; Callegaro D; Buchpiguel CA; de Paula Faria D
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4551-4566. PubMed ID: 35838758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early prognosticators of later TSPO-PET-measurable microglial activation in multiple sclerosis.
    Laaksonen S; Saraste M; Sucksdorff M; Nylund M; Vuorimaa A; Matilainen M; Heikkinen J; Airas L
    Mult Scler Relat Disord; 2023 Jul; 75():104755. PubMed ID: 37216883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gray Matter Atrophy in the Cortico-Striatal-Thalamic Network and Sensorimotor Network in Relapsing-Remitting and Primary Progressive Multiple Sclerosis.
    Cao Y; Diao W; Tian F; Zhang F; He L; Long X; Zhou F; Jia Z
    Neuropsychol Rev; 2021 Dec; 31(4):703-720. PubMed ID: 33582965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET.
    Nylund M; Sucksdorff M; Matilainen M; Polvinen E; Tuisku J; Airas L
    Brain Commun; 2022 Feb; 4(1):fcab301. PubMed ID: 34993478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
    Elliott C; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Wei W; Belachew S; Arnold DL
    Mult Scler; 2019 Dec; 25(14):1915-1925. PubMed ID: 30566027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
    Di Perri C; Battaglini M; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study.
    Schmierer K; Altmann DR; Kassim N; Kitzler H; Kerskens CM; Doege CA; Aktas O; Lünemann JD; Miller DH; Zipp F; Villringer A
    Mult Scler; 2004 Apr; 10(2):182-7. PubMed ID: 15124765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Widespread Glial Activation in Primary Progressive Multiple Sclerosis Revealed by 18F-PBR06 PET: A Clinically Feasible, Individualized Approach.
    Singhal T; Rissanen E; Ficke J; Cicero S; Carter K; Weiner HL
    Clin Nucl Med; 2021 Feb; 46(2):136-137. PubMed ID: 33208611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.